Literature DB >> 2360395

Parkinson's disease in Aberdeen: survival after 3.5 years.

K P Ebmeier1, S A Calder, J R Crawford, L Stewart, J A Besson, W J Mutch.   

Abstract

The increasing age of the general population and of patients suffering from Parkinson's disease suggests that a reappraisal of mortality rates and factors related to increased mortality should be carried out. A 3.5 year follow-up of a whole population sample of 267 patients and 233 controls matched by age, sex and general practitioner, yielded a relative mortality rate of 2.35 (99%-confidence interval: 1.60-3.43). Factors predicting death within the follow-up period were: cognitive impairment, old age, late age of onset, long history of smoking, lower blood pressure, and a variety of signs, symptoms and sequelae of Parkinson's disease associated with decreased mobility. However, age less than 70 years, age of onset before 66 years, absence of kyphosis or normal Webster posture score, mild impairment on the Hoehn & Yahr scale (1-2), or no impairment in a 10-question mental status questionnaire (9-10), were not associated with an increased risk of death.

Entities:  

Mesh:

Year:  1990        PMID: 2360395     DOI: 10.1111/j.1600-0404.1990.tb01558.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  12 in total

1.  The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years.

Authors:  M A Hely; J G Morris; R Traficante; W G Reid; D J O'Sullivan; P M Williamson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  Estimated life expectancy of Parkinson's patients compared with the UK population.

Authors:  Lianna S Ishihara; Anne Cheesbrough; Carol Brayne; Anette Schrag
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-30       Impact factor: 10.154

Review 3.  How far are we in understanding the cause of Parkinson's disease?

Authors:  Y Ben-Shlomo
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-07       Impact factor: 10.154

4.  Further evidence of increased risk of mortality of Parkinson's disease.

Authors:  F Tison; L Letenneur; F Djossou; J F Dartigues
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-05       Impact factor: 10.154

Review 5.  Dementia and co-occurring chronic conditions: a systematic literature review to identify what is known and where are the gaps in the evidence?

Authors:  Mark B Snowden; Lesley E Steinman; Lucinda L Bryant; Monique M Cherrier; Kurt J Greenlund; Katherine H Leith; Cari Levy; Rebecca G Logsdon; Catherine Copeland; Mia Vogel; Lynda A Anderson; David C Atkins; Janice F Bell; Annette L Fitzpatrick
Journal:  Int J Geriatr Psychiatry       Date:  2017-02-01       Impact factor: 3.485

6.  Factors affecting survival of patients with neurodegenerative disease.

Authors:  Kyle Steenland; Jessica MacNeil; Ryan Seals; Allan Levey
Journal:  Neuroepidemiology       Date:  2010-04-08       Impact factor: 3.282

Review 7.  Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?

Authors:  M G Murer; R Raisman-Vozari; O Gershanik
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

8.  NADPH Oxidase: a Possible Therapeutic Target for Cognitive Impairment in Experimental Cerebral Malaria.

Authors:  Simhadri Praveen Kumar; Phanithi Prakash Babu
Journal:  Mol Neurobiol       Date:  2021-11-16       Impact factor: 5.682

9.  Long-term survival of Parkinson's disease: a population-based study.

Authors:  M D'Amelio; P Ragonese; L Morgante; A Reggio; G Callari; G Salemi; G Savettieri
Journal:  J Neurol       Date:  2005-07-18       Impact factor: 6.682

10.  Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?

Authors:  Y Ben-Shlomo; M G Marmot
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-03       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.